A non-opioid topical cream that eases burn pain by blocking skin pain receptors
Official title: Topical treatment for burn pain by blocking cutaneous pain receptors.
Funded at Serentrix, LLC · NIH-11329917 · Data updated 2026-11-12
This project is creating a non-opioid skin cream that targets TRPV1 pain receptors to help people with burn-related pain feel less pain.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Serentrix, LLC NIH-funded |
| Lab location | 1 site (Exton, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $6,500 |
| NIH project number | 3R43GM150295-01A1S1 |
| Project ID | NIH-11329917 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with painful skin burns who want a topical, non-opioid option for acute or ongoing burn-related pain would be the ideal candidates for future testing.
✕Less likely to help
People with very deep full-thickness burns that need surgery, pain coming from deeper nerve or bone injury, or those who cannot use topical treatments are unlikely to benefit from a surface cream.
What this research studies
This work is developing a first-in-class topical medicine that blocks TRPV1 and related pain receptors in the skin to reduce burn pain. The current Phase I SBIR effort focuses on formulation, preclinical testing, and business and regulatory planning supported by technical and business assistance. The goal is to make a product ready for Phase II funding and for downstream partnering or licensing so clinical testing can follow. At this stage the grant supports commercialization steps rather than enrolling patients.
Why it matters
Potential benefit: If successful, this could offer meaningful non-opioid relief for burn pain with fewer systemic side effects and lower addiction risk.
How similar studies have gone: Some topical approaches that target skin pain receptors have shown promise in other pain conditions, but a first-in-class TRPV1-targeting topical specifically for burn pain is relatively novel and early-stage.
Where this research is happening
-
Serentrix, LLC
Exton, United States Active
Researchers
- Principal investigator: Bhargava, Kumaril — Serentrix, LLC
- Study coordinator: Bhargava, Kumaril
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.